anti-VEGF treatment in patients with diabetic macular edema
- Conditions
- Diabetic macular edemaTherapeutic area: Diseases [C] - Eye Diseases [C11]
- Registration Number
- EUCTR2015-003162-82-FI
- Lead Sponsor
- Raimo Tuuminen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients aged 18-70 years, BCVA 0.0625-0.8 Snellen
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 340
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 80
Exclusion Criteria
No wet-AMD, prior anti-VEGF therapy, artery or vein occlusion, retinal ablation, optic neuropathy, glaucoma, laserphotocoagulation, endophtalmitis, myopic degeneration, other antineoplastic drugs, severe cardiovascular disease
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method